drugset
drugset / Trial / NCT06213363

A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough

NCT06213363 ↗

Phase 1/2 Unknown 72 enrolled Beijing Tide Pharmaceutical Co., Ltd
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the effectiveness, safety, tolerability and pharmacokinetics (PK) of TCR1672 Tablets in patients with refractory chronic cough.

Timeline

Start
2024-02
Primary completion
2024-10
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TCR1672 Unknown 20 mg Oral
Subject TCR1672 Unknown 40 mg Oral
Subject TCR1672 Unknown 60 mg Oral

Indications

respiratory system disorder